Literature DB >> 11683249

Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.

D N Waterhouse1, N Dos Santos, L D Mayer, M B Bally.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11683249     DOI： 10.1023/a:1013050330608

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  27 in total

1.  Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.

Authors:  H J Lim; D Masin; T D Madden; M B Bally
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

2.  First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.

Authors:  S Kakolyris; G Samonis; M Koukourakis; J Vlachonicolis; K Kalbakis; S Agelaki; G Chalkiadakis; E Sanidas; D Tsiftsis; V Georgoulias
Journal:  Am J Clin Oncol       Date:  1999-06       Impact factor: 2.339

3.  Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma.

Authors:  A Avilés; J Halabe
Journal:  Cancer Biother Radiopharm       Date:  1999-10       Impact factor: 3.099

4.  Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

Authors:  A H Sarris; F Hagemeister; J Romaguera; M A Rodriguez; P McLaughlin; A M Tsimberidou; L J Medeiros; B Samuels; O Pate; M Oholendt; H Kantarjian; C Burge; F Cabanillas
Journal:  Ann Oncol       Date:  2000-01       Impact factor: 32.976

Review 5.  Liposomal doxorubicin.

Authors:  P G Tardi; N L Boman; P R Cullis
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

6.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.

Authors:  A Chonn; S C Semple; P R Cullis
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

7.  Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation.

Authors:  L D Mayer; J Reamer; M B Bally
Journal:  J Pharm Sci       Date:  1999-01       Impact factor: 3.534

Review 8.  Rationale for chemotherapeutic approaches to prostate cancer.

Authors:  P J Creaven
Journal:  Prostate       Date:  1984       Impact factor: 4.104

9.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  Influence of cholesterol on the association of plasma proteins with liposomes.

Authors:  S C Semple; A Chonn; P R Cullis
Journal:  Biochemistry       Date:  1996-02-27       Impact factor: 3.162
View more
  1 in total

Review 1.  Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.

Authors:  Trisha A Soosay Raj; Amanda M Smith; Andrew S Moore
Journal:  Int J Nanomedicine       Date:  2013-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.